![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, November 18, 2009 5:10:40 PM
Tuesday, 17 November 2009 06:40
Rodman & Renshaw gave the Biotechnology industry some bad news as it announced a downgrade on one of its stocks.
Poniard Pharmaceuticals, Inc. (PARD) [Chart - News - Analysis] was downgraded from Mkt Outperform » Mkt Perform on 11/17/2009---a negative sign for the stock that investors will have to endure. FYI, Rodman & Renshaw uses the following rating scale when analyzing stocks: Mkt Outperform, Mkt Perform, Mkt Underperform, Under Review.
http://www.learningmarkets.com/index.php/200911178777/News-Feed/News-Feed/poniard-pharmaceuticals-inc-endures-analyst-downgrade-pard-ilmn-genz.html
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM
Element79 Gold Corp Files for OTCQB Uplisting, Provides Financial Update • ELEM • Jun 11, 2024 9:25 AM